Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-10-06

AUTHORS

G. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, R. R. Recker, D. Felsenberg

ABSTRACT

Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis.IntroductionTreatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-term extension (LTE) to the 2-year DIVA trial.MethodsDIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≥75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate.ResultsPooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXA-BMD (8.4% [95% confidence interval (CI) = 7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI = 7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed.ConclusionsTreatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis. More... »

PAGES

1769-1778

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9

DOI

http://dx.doi.org/10.1007/s00198-011-1793-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1038256783

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21975558


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Absorptiometry, Photon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ibandronic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Longitudinal Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lumbar Vertebrae", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis, Postmenopausal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bianchi", 
        "givenName": "G.", 
        "id": "sg:person.0607571556.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607571556.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Krakow Medical Centre, Krakow, Poland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Krakow Medical Centre, Krakow, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Czerwinski", 
        "givenName": "E.", 
        "id": "sg:person.0637750557.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637750557.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Roche Products Limited, Welwyn Garden City, UK", 
          "id": "http://www.grid.ac/institutes/grid.419227.b", 
          "name": [
            "Roche Products Limited, Welwyn Garden City, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kenwright", 
        "givenName": "A.", 
        "id": "sg:person.0654675727.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654675727.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "F. Hoffmann-La Roche Ltd., Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.417570.0", 
          "name": [
            "F. Hoffmann-La Roche Ltd., Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burdeska", 
        "givenName": "A.", 
        "id": "sg:person.013722740000.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722740000.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Osteoporosis Research Center, Creighton University, Omaha, NE, USA", 
          "id": "http://www.grid.ac/institutes/grid.254748.8", 
          "name": [
            "Osteoporosis Research Center, Creighton University, Omaha, NE, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Recker", 
        "givenName": "R. R.", 
        "id": "sg:person.016325222544.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Charit\u00e9\u2014Campus Benjamin Franklin, Freie and Humboldt-Universit\u00e4t Berlin, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.6363.0", 
          "name": [
            "Charit\u00e9\u2014Campus Benjamin Franklin, Freie and Humboldt-Universit\u00e4t Berlin, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Felsenberg", 
        "givenName": "D.", 
        "id": "sg:person.01210634005.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210634005.52"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00198-006-0322-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012288373", 
          "https://doi.org/10.1007/s00198-006-0322-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-003-1435-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052883806", 
          "https://doi.org/10.1007/s00198-003-1435-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0653-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052235097", 
          "https://doi.org/10.1007/s00198-008-0653-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03346353", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022747871", 
          "https://doi.org/10.1007/bf03346353"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200730090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052609562", 
          "https://doi.org/10.2165/00002018-200730090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-200932090-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051242423", 
          "https://doi.org/10.2165/00002018-200932090-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.14310/horm.2002.1226", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1067262245", 
          "https://doi.org/10.14310/horm.2002.1226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11914-009-0003-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015034231", 
          "https://doi.org/10.1007/s11914-009-0003-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-011-1549-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040089691", 
          "https://doi.org/10.1007/s00198-011-1549-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00223-004-0286-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007415759", 
          "https://doi.org/10.1007/s00223-004-0286-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200666120-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010970356", 
          "https://doi.org/10.2165/00003495-200666120-00005"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-10-06", 
    "datePublishedReg": "2011-10-06", 
    "description": "Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3\u00a0mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5\u00a0years (8.1%) and was well tolerated in women with postmenopausal osteoporosis.IntroductionTreatment with IV ibandronate regimens, 2\u00a0mg bimonthly and 3\u00a0mg quarterly, has been studied for up to 5\u00a0years in a long-term extension (LTE) to the 2-year DIVA trial.MethodsDIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2\u00a0years of DIVA core, comparing daily oral and IV ibandronate (\u226575% adherence with IV ibandronate in year\u00a02 of DIVA). Patients previously treated with 2\u00a0mg bimonthly or 3\u00a0mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5\u00a0mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate.ResultsPooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5\u00a0years in lumbar spine DXA-BMD (8.4% [95% confidence interval (CI)\u2009=\u20097.5, 9.3] with 2\u00a0mg bimonthly and 8.1% [95% CI\u2009=\u20097.2, 8.9] with 3\u00a0mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed.ConclusionsTreatment with IV ibandronate 2\u00a0mg bimonthly or 3\u00a0mg quarterly is effective and well tolerated for up to 5\u00a0years in women with postmenopausal osteoporosis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-011-1793-9", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "23"
      }
    ], 
    "keywords": [
      "long-term extension", 
      "postmenopausal osteoporosis", 
      "lumbar spine bone mineral density", 
      "DXA-BMD", 
      "bone mineral density gains", 
      "spine bone mineral density", 
      "dual-energy X-ray absorptiometry", 
      "quarterly intravenous ibandronate", 
      "daily oral ibandronate", 
      "full ITT population", 
      "open-label extension", 
      "bone marker levels", 
      "new safety signals", 
      "long-term administration", 
      "bone mineral density", 
      "X-ray absorptiometry", 
      "intravenous ibandronate", 
      "ibandronate regimens", 
      "oral ibandronate", 
      "placebo IV", 
      "ITT population", 
      "postmenopausal women", 
      "same regimen", 
      "treat patients", 
      "tolerability concerns", 
      "marker levels", 
      "administration trial", 
      "bone metabolism", 
      "mineral density", 
      "safety signals", 
      "ibandronate", 
      "sustained reduction", 
      "patients", 
      "osteoporosis", 
      "women", 
      "trials", 
      "baseline", 
      "dive trials", 
      "core baseline", 
      "years", 
      "consistent increase", 
      "regimens", 
      "regimen", 
      "IntroductionTreatment", 
      "noninferiority", 
      "ConclusionsTreatment", 
      "absorptiometry", 
      "administration", 
      "three-year data", 
      "markers", 
      "metabolism", 
      "safety", 
      "population", 
      "further gains", 
      "levels", 
      "data", 
      "gain", 
      "density gain", 
      "study", 
      "benefits", 
      "intent", 
      "increase", 
      "reduction", 
      "maintenance", 
      "concern", 
      "analysis", 
      "extension", 
      "signals", 
      "density", 
      "core"
    ], 
    "name": "Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension", 
    "pagination": "1769-1778", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1038256783"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-011-1793-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21975558"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-011-1793-9", 
      "https://app.dimensions.ai/details/publication/pub.1038256783"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T16:59", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_554.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-011-1793-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-011-1793-9'


 

This table displays all metadata directly associated to this object as RDF triples.

300 TRIPLES      21 PREDICATES      125 URIs      106 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-011-1793-9 schema:about N0270f6e8f8924a119275a8d53b7b85f0
2 N03773ecf123a4c569ea63c65117959fe
3 N1189580c6aa543baafbd9ab5e3190034
4 N26d79c25ee9044de9cfe52c3a57fa95a
5 N2ef6ef0269884f93bcfac99c595c04ba
6 N49408381d3d64f248e122f50ce0edf3c
7 N5f936b13c4814bdeb399f1f10f7f3cef
8 N60158f3b82b54a95a27ba7b26879ccdf
9 N620399e0b92245a78d8831952d81b71c
10 N6cb52870478842a4b0d633da124a3b94
11 N6d726bff001b4fb0b73416b95345be06
12 N8fb7934b6eee4352bf09f8e16faa98bf
13 N9edffe7f40554ed1bb8fb70ae47d6200
14 N9fb0f22df41b40c0866577c04eae5b07
15 Na8c1d3c1a54d4bbb8bcd552bd885e08d
16 Na8d85f4f8b4e49c088190f60c2f5a169
17 Nd5dedc71252f408f8af550c97de94669
18 Ne765d746a18748eda4f2b6dd353ac73c
19 Nf48e935152a04a33b135c1fe48b0fd56
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N2129c45edd9d4e3a96a57695772f8db0
23 schema:citation sg:pub.10.1007/bf03346353
24 sg:pub.10.1007/s00198-003-1435-y
25 sg:pub.10.1007/s00198-006-0322-8
26 sg:pub.10.1007/s00198-008-0653-8
27 sg:pub.10.1007/s00198-011-1549-6
28 sg:pub.10.1007/s00223-004-0286-7
29 sg:pub.10.1007/s11914-009-0003-6
30 sg:pub.10.14310/horm.2002.1226
31 sg:pub.10.2165/00002018-200730090-00003
32 sg:pub.10.2165/00002018-200932090-00002
33 sg:pub.10.2165/00003495-200666120-00005
34 schema:datePublished 2011-10-06
35 schema:datePublishedReg 2011-10-06
36 schema:description Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis.IntroductionTreatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-term extension (LTE) to the 2-year DIVA trial.MethodsDIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≥75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate.ResultsPooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXA-BMD (8.4% [95% confidence interval (CI) = 7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI = 7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed.ConclusionsTreatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.
37 schema:genre article
38 schema:isAccessibleForFree false
39 schema:isPartOf N66787796f5484431966ef7a9dca23235
40 Nedb4ce012837427681a6d693c418d7e7
41 sg:journal.1100834
42 schema:keywords ConclusionsTreatment
43 DXA-BMD
44 ITT population
45 IntroductionTreatment
46 X-ray absorptiometry
47 absorptiometry
48 administration
49 administration trial
50 analysis
51 baseline
52 benefits
53 bone marker levels
54 bone metabolism
55 bone mineral density
56 bone mineral density gains
57 concern
58 consistent increase
59 core
60 core baseline
61 daily oral ibandronate
62 data
63 density
64 density gain
65 dive trials
66 dual-energy X-ray absorptiometry
67 extension
68 full ITT population
69 further gains
70 gain
71 ibandronate
72 ibandronate regimens
73 increase
74 intent
75 intravenous ibandronate
76 levels
77 long-term administration
78 long-term extension
79 lumbar spine bone mineral density
80 maintenance
81 marker levels
82 markers
83 metabolism
84 mineral density
85 new safety signals
86 noninferiority
87 open-label extension
88 oral ibandronate
89 osteoporosis
90 patients
91 placebo IV
92 population
93 postmenopausal osteoporosis
94 postmenopausal women
95 quarterly intravenous ibandronate
96 reduction
97 regimen
98 regimens
99 safety
100 safety signals
101 same regimen
102 signals
103 spine bone mineral density
104 study
105 sustained reduction
106 three-year data
107 tolerability concerns
108 treat patients
109 trials
110 women
111 years
112 schema:name Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension
113 schema:pagination 1769-1778
114 schema:productId Nb078dd28e7c44772adec7983eccc172b
115 Nddc78961058c485795bd7d55fedd3671
116 Nea0351d57f4042c2ae2aac39af053846
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038256783
118 https://doi.org/10.1007/s00198-011-1793-9
119 schema:sdDatePublished 2022-08-04T16:59
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N884cb039fedd4b03823a913cbcd34532
122 schema:url https://doi.org/10.1007/s00198-011-1793-9
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N0270f6e8f8924a119275a8d53b7b85f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Longitudinal Studies
128 rdf:type schema:DefinedTerm
129 N03773ecf123a4c569ea63c65117959fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Biomarkers
131 rdf:type schema:DefinedTerm
132 N08489e7125644b51b349de596b022f83 rdf:first sg:person.01210634005.52
133 rdf:rest rdf:nil
134 N1189580c6aa543baafbd9ab5e3190034 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Osteoporosis, Postmenopausal
136 rdf:type schema:DefinedTerm
137 N1346c9c4ebc743f9b00422d327b0a1cb rdf:first sg:person.013722740000.32
138 rdf:rest Ncefacbf977104ef59ae8d34efeeb9c91
139 N2129c45edd9d4e3a96a57695772f8db0 rdf:first sg:person.0607571556.89
140 rdf:rest Nd08729942d00418382e51b8ed07a6b2f
141 N26d79c25ee9044de9cfe52c3a57fa95a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Female
143 rdf:type schema:DefinedTerm
144 N2ef6ef0269884f93bcfac99c595c04ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N49408381d3d64f248e122f50ce0edf3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Humans
149 rdf:type schema:DefinedTerm
150 N5f936b13c4814bdeb399f1f10f7f3cef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Bone Density
152 rdf:type schema:DefinedTerm
153 N60158f3b82b54a95a27ba7b26879ccdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Double-Blind Method
155 rdf:type schema:DefinedTerm
156 N620399e0b92245a78d8831952d81b71c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Aged, 80 and over
158 rdf:type schema:DefinedTerm
159 N66787796f5484431966ef7a9dca23235 schema:issueNumber 6
160 rdf:type schema:PublicationIssue
161 N6cb52870478842a4b0d633da124a3b94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Absorptiometry, Photon
163 rdf:type schema:DefinedTerm
164 N6d726bff001b4fb0b73416b95345be06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Lumbar Vertebrae
166 rdf:type schema:DefinedTerm
167 N72eb4c0500c045e6ac726c82b64b4371 rdf:first sg:person.0654675727.29
168 rdf:rest N1346c9c4ebc743f9b00422d327b0a1cb
169 N884cb039fedd4b03823a913cbcd34532 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 N8fb7934b6eee4352bf09f8e16faa98bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Bone Density Conservation Agents
173 rdf:type schema:DefinedTerm
174 N9edffe7f40554ed1bb8fb70ae47d6200 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Infusions, Intravenous
176 rdf:type schema:DefinedTerm
177 N9fb0f22df41b40c0866577c04eae5b07 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged
179 rdf:type schema:DefinedTerm
180 Na8c1d3c1a54d4bbb8bcd552bd885e08d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Treatment Outcome
182 rdf:type schema:DefinedTerm
183 Na8d85f4f8b4e49c088190f60c2f5a169 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Drug Administration Schedule
185 rdf:type schema:DefinedTerm
186 Nb078dd28e7c44772adec7983eccc172b schema:name dimensions_id
187 schema:value pub.1038256783
188 rdf:type schema:PropertyValue
189 Ncefacbf977104ef59ae8d34efeeb9c91 rdf:first sg:person.016325222544.69
190 rdf:rest N08489e7125644b51b349de596b022f83
191 Nd08729942d00418382e51b8ed07a6b2f rdf:first sg:person.0637750557.76
192 rdf:rest N72eb4c0500c045e6ac726c82b64b4371
193 Nd5dedc71252f408f8af550c97de94669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Administration, Oral
195 rdf:type schema:DefinedTerm
196 Nddc78961058c485795bd7d55fedd3671 schema:name doi
197 schema:value 10.1007/s00198-011-1793-9
198 rdf:type schema:PropertyValue
199 Ne765d746a18748eda4f2b6dd353ac73c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Diphosphonates
201 rdf:type schema:DefinedTerm
202 Nea0351d57f4042c2ae2aac39af053846 schema:name pubmed_id
203 schema:value 21975558
204 rdf:type schema:PropertyValue
205 Nedb4ce012837427681a6d693c418d7e7 schema:volumeNumber 23
206 rdf:type schema:PublicationVolume
207 Nf48e935152a04a33b135c1fe48b0fd56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Ibandronic Acid
209 rdf:type schema:DefinedTerm
210 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
211 schema:name Medical and Health Sciences
212 rdf:type schema:DefinedTerm
213 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
214 schema:name Clinical Sciences
215 rdf:type schema:DefinedTerm
216 sg:journal.1100834 schema:issn 0937-941X
217 1433-2965
218 schema:name Osteoporosis International
219 schema:publisher Springer Nature
220 rdf:type schema:Periodical
221 sg:person.01210634005.52 schema:affiliation grid-institutes:grid.6363.0
222 schema:familyName Felsenberg
223 schema:givenName D.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210634005.52
225 rdf:type schema:Person
226 sg:person.013722740000.32 schema:affiliation grid-institutes:grid.417570.0
227 schema:familyName Burdeska
228 schema:givenName A.
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722740000.32
230 rdf:type schema:Person
231 sg:person.016325222544.69 schema:affiliation grid-institutes:grid.254748.8
232 schema:familyName Recker
233 schema:givenName R. R.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016325222544.69
235 rdf:type schema:Person
236 sg:person.0607571556.89 schema:affiliation grid-institutes:None
237 schema:familyName Bianchi
238 schema:givenName G.
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0607571556.89
240 rdf:type schema:Person
241 sg:person.0637750557.76 schema:affiliation grid-institutes:None
242 schema:familyName Czerwinski
243 schema:givenName E.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637750557.76
245 rdf:type schema:Person
246 sg:person.0654675727.29 schema:affiliation grid-institutes:grid.419227.b
247 schema:familyName Kenwright
248 schema:givenName A.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654675727.29
250 rdf:type schema:Person
251 sg:pub.10.1007/bf03346353 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022747871
252 https://doi.org/10.1007/bf03346353
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00198-003-1435-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052883806
255 https://doi.org/10.1007/s00198-003-1435-y
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s00198-006-0322-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012288373
258 https://doi.org/10.1007/s00198-006-0322-8
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s00198-008-0653-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052235097
261 https://doi.org/10.1007/s00198-008-0653-8
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s00198-011-1549-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040089691
264 https://doi.org/10.1007/s00198-011-1549-6
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s00223-004-0286-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007415759
267 https://doi.org/10.1007/s00223-004-0286-7
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/s11914-009-0003-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015034231
270 https://doi.org/10.1007/s11914-009-0003-6
271 rdf:type schema:CreativeWork
272 sg:pub.10.14310/horm.2002.1226 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067262245
273 https://doi.org/10.14310/horm.2002.1226
274 rdf:type schema:CreativeWork
275 sg:pub.10.2165/00002018-200730090-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052609562
276 https://doi.org/10.2165/00002018-200730090-00003
277 rdf:type schema:CreativeWork
278 sg:pub.10.2165/00002018-200932090-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051242423
279 https://doi.org/10.2165/00002018-200932090-00002
280 rdf:type schema:CreativeWork
281 sg:pub.10.2165/00003495-200666120-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010970356
282 https://doi.org/10.2165/00003495-200666120-00005
283 rdf:type schema:CreativeWork
284 grid-institutes:None schema:alternateName Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy
285 Krakow Medical Centre, Krakow, Poland
286 schema:name Division of Rheumatology, Azienda Sanitaria Genovese, Genoa, Italy
287 Krakow Medical Centre, Krakow, Poland
288 rdf:type schema:Organization
289 grid-institutes:grid.254748.8 schema:alternateName Osteoporosis Research Center, Creighton University, Omaha, NE, USA
290 schema:name Osteoporosis Research Center, Creighton University, Omaha, NE, USA
291 rdf:type schema:Organization
292 grid-institutes:grid.417570.0 schema:alternateName F. Hoffmann-La Roche Ltd., Basel, Switzerland
293 schema:name F. Hoffmann-La Roche Ltd., Basel, Switzerland
294 rdf:type schema:Organization
295 grid-institutes:grid.419227.b schema:alternateName Roche Products Limited, Welwyn Garden City, UK
296 schema:name Roche Products Limited, Welwyn Garden City, UK
297 rdf:type schema:Organization
298 grid-institutes:grid.6363.0 schema:alternateName Charité—Campus Benjamin Franklin, Freie and Humboldt-Universität Berlin, Berlin, Germany
299 schema:name Charité—Campus Benjamin Franklin, Freie and Humboldt-Universität Berlin, Berlin, Germany
300 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...